Sexual function and quality of life after the creation of a neovagina in women with Mayer-Rokitansky-Kuster-Hauser syndrome: comparison of vaginal dilation and surgical procedures
Sexual function and quality of life after the creation of a neovagina in women with Mayer-Rokitansky-Kuster-Hauser syndrome: comparison of vaginal dilation and surgical procedures
复制标题
患有 Mayer-Rokitansky-Küster-Hauser 综合征的女性新阴道形成后的性功能和生活质量：阴道扩张和手术程序的比较
DOI：
10.1016/j.fertnstert.2020.01.017
复制
发表时间：
2020-05-01
影响因子：
6.7
通讯作者：
Zhu, Lan
中科院分区：
文献类型：
--
作者：
Kang, Jia;Chen, Na;Zhu, Lan
目的：比较阴道扩张和外科手术后Mayer-Roldtansky-Kuster-Hauser（MRKH）综合征患者的性功能和生活质量结局。研究设计：2019年1月至2019年6月的横断面研究。设置：三级教学医院。患者：接受阴道扩张（n = 88）或外科手术（n = 45）治疗的MRKH综合征女性。干预：主要观察指标：采用女性性功能指数（FSFI）评定患者的性功能。生活质量的结果通过12项世界卫生组织残疾评估表2（WHODAS 2）进行评估。阴道长度定义为阴道模具放置的最大深度。结果：扩张组（24.49 ± 4.51）和手术组（23.79 ± 3.57）的FSFI评分相似。除了扩张组的性高潮评分较高（9.96 +/- 3.60 vs. 8.20 +/- 2.67）外，FSFI的其他维度在两组之间没有显著差异。扩张组（中位数8.33 [四分位数间距4.17-15.62]）和手术组（6.25 [2.08-14.58]）的WHODAS 2评分无显著差异。结论：尽管扩张治疗组阴道长度较手术治疗组短，但两组患者的性功能和生活质量相似。建议将阴道扩张作为MRKH患者的一线治疗。(C)2020年，美国生殖医学会。
Objective: To compare sexual function and outcomes of quality of life of patients with Mayer-Roldtansky-Kuster-Hauser (MRKH) syndrome after vaginal dilation and surgical procedures.Study Design: Cross-sectional study from January 2019 to June 2019.Setting: Tertiary teaching hospital.Patient(s): Women with MRKH syndrome treated with vaginal dilation (n = 88) or surgical procedures (n = 45).Intervention: WeChat-based questionnaires were distributed to every group member in our MRKH support group.Main Outcome Measure(s): Sexual functional were assessed by means of the Female Sexual Function Index (FSFI). Outcomes of quality of life were assessed by means of the 12-item World Health Organization Disability Assessment Schedule 2 (WHODAS2). Vaginal length was defined as the maximum depth of the placement of the vaginal mold.Result(s): The FSFI scores were similar between the dilation (24.49 +/- 4.51) and surgery (23.79 +/- 3.57) groups. Except for the higher orgasm score in the dilation group (9.96 +/- 3.60 vs. 8.20 +/- 2.67), the other dimensions of the FSFI were not significantly different be- tween the groups. No significant differences were found in the WHODAS2 scores between the dilation group (median 8.33 (interquartile range 4.17-15.62]) and the surgery group (6.25 [2.08-14.58]). However, the vaginal length was significantly shorter in the dilation group (6.5 +/- 2.04 cm) than in the surgery group (8.1 +/- 1.59 cm).Conclusion(s): Although the vaginal length was shorter in the dilation therapy group than in the surgical therapy group, sexual function and quality of life were similar between these two groups. Vaginal dilation should be proposed as the first-line therapy for MRKH patients. (C) 2020 by American Society for Reproductive Medicine.